EP News Clinical November 2020

Okumura and colleagues (N Eng J Med 2020 Oct 29;383(18):1735-1745. PMID: 32865374) conducted a multicenter, randomized, double-blind, placebo-controlled, trial to compare a once-daily 15-mg dose of edoxaban (E) with placebo in elderly patients ( ≥80 years of age) with nonvalvular atrial fibrillation who were not candidates for oral anticoagulant therapy at doses approved for stroke prevention. The primary efficacy end point was the composite of stroke or systemic embolism. A total of 984 patients were randomly assigned in a 1:1 ratio to r eceive a daily dose of 15 mg of E (492 patients) or placebo (492 patients).
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research